PURPOSE: To compare characteristic findings of 18F-FDG PET/CT with ultrasonography of malignant thyroid incidentaloma. MATERIALS AND METHODS: This study enrolled 74 patients receiving ultrasonography after thyroid incidentaloma detected on 18F-FDG PET/CT. We analyzed the size, attenuation, margin, cervical lymphadenopathy, and P-SUV of thyroid incidentaloma in 18F-FDG PET/CT and analyzed the size, internal contents, appearance, border, echo, and calcification patterns of thyroid incidentaloma in ultrasonography. Based on pathologic findings, we investigated findings of 18F-FDG PET/CT and ultrasonography for malignant thyroid incidentaloma. RESULTS: In 18F-FDG PET/CT findings, an ill-defined margin accompanied by cervical lymphadenopathy was more common in malignant (59.1%) than benign (13.2%) lesions (p < 0.05). There were no significant differences in p-SUV between malignant and benign thyroid incidentalomas (4.8+/-18.3 vs. 4.4+/-2.2). In ultrasonographic findings, being taller than wide (1.9% vs. 36.4%), having a well-defined speculated margin (75.5% vs. 22.7%), having marked hypoechoic images (18.9% vs. 31.8%), and having micro (5.7% vs. 22.7%) or macrocalcifications (3.8% vs. 27.3%) were more common in malignant thyroid incidentalomas (p < 0.05). CONCLUSION: Malignant thyroid incidentalomas in 18F-FDG PET/CT have ill-defined margins, and those in ultrasonography were the taller than wide, well defined spiculated margin, and showed micro or macrocalcification.
Fluorodeoxyglucose F18 ; Humans ; Lymphatic Diseases ; Thyroid Gland

The Committee of Central Precocious Puberty of Korean Pediatrics and Adolescents of the Korean Society of Pediatric Endocrinology has newly developed evidence-based 2022 clinical practice guidelines for central precocious puberty in Korean children and adolescents. These guidelines provide the grade of recommendations, which includes both the strength of recommendations and the level of evidence. In the absence of sufficient evidence, recommendations are based on expert opinion. These guidelines have been revised and supplement the previous guidelines "Clinical Guidelines for Precocious Puberty 2011," and are drawn from a comprehensive review of the latest domestic and international research and the grade of recommendation appropriate to the domestic situation. This review summarizes the newly revised guidelines into 8 key questions and 27 recommendations and consists of 4 sections: screening, diagnosis, treatment, and long-term outcome of central precocious puberty.